Evidence map›Paper›PMID 38892228›Full record

ArticleInternational journal of molecular sciences2024

Machine Learning Identifies Key Proteins in Primary Sclerosing Cholangitis Progression and Links High CCL24 to Cirrhosis.

Tom Snir, Raanan Greenman, Revital Aricha, Matthew Frankel, John Lawler, Francesca Saffioti, Massimo Pinzani, Douglas Thorburn, Adi Mor, Ilan Vaknin

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Cholangiocarcinoma: The era of liquid biopsy.World journal of gastroenterology · 2025
    Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tom SnirChemomab Therapeutics Ltd., Tel Aviv 6158002, Israel.
Raanan GreenmanChemomab Therapeutics Ltd., Tel Aviv 6158002, Israel.ORCID 0009-0001-9634-4638
Revital ArichaChemomab Therapeutics Ltd., Tel Aviv 6158002, Israel.
Matthew FrankelChemomab Therapeutics Ltd., Tel Aviv 6158002, Israel.
John LawlerChemomab Therapeutics Ltd., Tel Aviv 6158002, Israel.
Francesca SaffiotiUCL Institute for Liver and Digestive Health, University College of London, London NW3 2PF, UK.ORCID 0000-0001-7635-9931
Massimo PinzaniUCL Institute for Liver and Digestive Health, University College of London, London NW3 2PF, UK.
Douglas ThorburnUCL Institute for Liver and Digestive Health, University College of London, London NW3 2PF, UK.
Adi MorChemomab Therapeutics Ltd., Tel Aviv 6158002, Israel.
Ilan VakninChemomab Therapeutics Ltd., Tel Aviv 6158002, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary sclerosing cholangitis (PSC) is a rare, progressive disease, characterized by inflammation and fibrosis of the bile ducts, lacking reliable prognostic biomarkers for disease activity. Machine learning applied to broad proteomic profiling of sera allowed for the discovery of markers of disease presence, severity, and cirrhosis and the exploration of the involvement of CCL24, a chemokine with fibro-inflammatory activity. Sera from 30 healthy controls and 45 PSC patients were profiled with proximity extension assay, quantifying the expression of 2870 proteins, and used to train an elastic net model. Proteins that contributed most to the model were tested for correlation to enhanced liver fibrosis (ELF) score and used to perform pathway analysis. Statistical modeling for the presence of cirrhosis was performed with principal component analysis (PCA), and receiver operating characteristics (ROC) curves were used to assess the useability of potential biomarkers. The model successfully predicted the presence of PSC, where the top-ranked proteins were associated with cell adhesion, immune response, and inflammation, and each had an area under receiver operator characteristic (AUROC) curve greater than 0.9 for disease presence and greater than 0.8 for ELF score. Pathway analysis showed enrichment for functions associated with PSC, overlapping with pathways enriched in patients with high levels of CCL24. Patients with cirrhosis showed higher levels of CCL24. This data-driven approach to characterize PSC and its severity highlights potential serum protein biomarkers and the importance of CCL24 in the disease, implying its therapeutic potential in PSC.

Indexed as

BiomarkersChemokine CCL24Cholangitis, SclerosingLiver CirrhosisMachine LearningAdultCase-Control StudiesDisease ProgressionFemaleHumansMaleMiddle AgedProteomicsROC CurveBiomarkersCCL24 protein, humanChemokine CCL24CCL24clinical datamachine learningprimary sclerosing cholangitisproteomics

Identifiers

PMID38892228
PMCPMC11173115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.